Fast Five Quiz: Non–Small Cell Lung Cancer (NSCLC) and RET Mutation

Maurie Markman, MD


August 22, 2022

Liquid biopsies have been shown to detect not only oncogenic driver mutations for advanced NSCLC, but also RET mutations acquired as resistance alterations to targeted therapy. These mutations include RET V804 gatekeeper mutation; solvent front mutations G810S/R/C; and acquired alterations in other genes, such as EGFR, BRAF, and PIK3CA.

Tissue biopsies must be performed at disease progression in order to identify acquired mutations. However, tissue biopsies are limited, and a comprehensive genomic analysis may be the best method of detecting RET rearrangements.

RET rearrangements appear to be associated with a high risk for brain metastasis.

Learn more about NSCLC workup and diagnosis.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.